Avastin as monotherapy for retinopathy of prematurity

Journal of AAPOS

Volumn 14, Issue 1, 2010, Pages 2-3

  Mintz Hittner, Helen A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

DISEASE SEVERITY; EDITORIAL; HUMAN; LASER COAGULATION; MEDICAL DECISION MAKING; MONOTHERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; RETROLENTAL FIBROPLASIA; TREATMENT OUTCOME; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; INFANT, NEWBORN; RETINOPATHY OF PREMATURITY;

EID: 77749237149     PISSN: 10918531     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaapos.2009.12.002     Document Type: Editorial

References (3)

1. Law J.C., Recchia F.M., Morrison D., and Estes R. Intravitreal bevacizumab (Avastin) as adjunctive treatment for retinopathy of prematurity (ROP). J AAPOS 14 (2010) 6-10
2. Avery R.L. Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: Promise and concern. J AAPOS 13 (2009) 329-331
3. Kong L., Mintz-Hittner H.A., Penland R.L., Kretzer F.L., and Chevez-Barrios P. Intravitreal bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: A morphologic study. Arch Ophthalmol 126 (2008) 1161-1163